From: Systematic review of outcome measures in pediatric eosinophilic esophagitis treatment trials
 | Konikoff [18] | Schaeffer [19] | Dohil [20] | Assa’ad [21] | Spergel [22] | Gupta [23] | Page [25] NCT01458418 | Di Nardo [26] NCT01846962 | Teva Pharm [27] NCT00635089 | McGuire Davis [28] NCT01821898 | Heine [24] ACTRN12613001210763 |
---|---|---|---|---|---|---|---|---|---|---|---|
Esophageal eosinophilia or histologic remission (eosinophils/HPF) | X | Â | X | X | X | Â | X | Â | Â | X | X |
Biopsy Grade | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Compound histologic and symptom response | Â | Â | Â | Â | Â | X | Â | Â | Â | Â | Â |
Physician Global assessment score | Â | Â | Â | Â | X | Â | Â | Â | Â | Â | Â |
EoE clinical symptom score | Â | Â | Â | Â | Â | X | Â | Â | Â | Â | Â |
Clinical severity score | Â | Â | Â | Â | Â | Â | Â | X | Â | Â | Â |
Safety | Â | Â | Â | X | Â | Â | Â | Â | X | Â | Â |
Tolerability | Â | Â | Â | X | Â | Â | Â | Â | Â | Â | Â |
Pharmacokinetics | Â | Â | Â | X | Â | Â | Â | Â | Â | Â | Â |